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Abstract
The cyclin-dependent kinases (Cdks) regulate many cellular processes, including the cell cycle, neuronal
development, transcription, and posttranscriptional processing. To perform their functions, Cdks bind to specific
cyclin subunits to form a functional and active cyclin/Cdk complex. This review is focused on Cyclin K, which was
originally considered an alternative subunit of Cdk9, and on its newly identified partners, Cdk12 and Cdk13. We
briefly summarize research devoted to each of these proteins. We also discuss the proteins’ functions in the
regulation of gene expression via the phosphorylation of serine 2 in the C-terminal domain of RNA polymerase II,
contributions to the maintenance of genome stability, and roles in the onset of human disease and embryo
development.
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Introduction
The family of cyclin-dependent kinases (Cdks) consists
of 21 proteins whose activities usually require associa-
tion with a specific cyclin subunit [1]. The first Cdks to
be described were regulators of the cell cycle, such as
Cdk1, Cdk2, Cdk4, and Cdk6. Their corresponding
cyclins are also the most well characterized [2,3].
Another group of cyclin/Cdk complexes, including
cyclin H/Cdk7 and cyclin T/Cdk9, have cell cycle-inde-
pendent activities. These complexes are engaged in the
regulation of transcription and posttrancriptional mRNA
processing via the phosphorylation of the C-terminal
domain (CTD) of RNA polymerase II (RNAPII) and
other transcriptional regulators, such as DRB (5,6-
dichloro-1-ß-D-ribofuranosylbenzimidazole) sensitivity
inducing factor (DSIF) or negative elongation factor
(NELF) [4]. Recent work led to the characterization of
new transcription cycle-related Cdk complexes: cyclin
K/cyclin-dependent kinase 12 (CycK/Cdk12) and CycK/
Cdk13 [5,6]. In addition, it has been shown that CycK/
Cdk12 maintains genome stability by regulating the
expression of several important DNA damage response
(DDR) genes [5,7]. These findings were fueled by recent
developments in the field of RNAPII-mediated tran-
scription that led to: 1) increased interest in the
elucidation of the CTD code [4,8]; 2) the finding that
promoter-paused RNAPII and elongation represent
important regulatory steps in gene expression [9,10]; 3)
the conclusion that phosphorylation of the CTD couples
transcription to other cellular processes [11-13]; and 4)
clarification of the relationship between what was con-
sidered to be the only human serine 2 (Ser2) CTD
kinase, Cdk9, and its two putative yeast homologs, Bur1
and Ctk1 [6,14].
A brief history of CycK, Cdk12, and Cdk13
CycK
Human CycK was first identified as a protein that can
rescue the lethality caused by deletion of the G1 cyclin
genes CLN1, CLN2,a n dCLN3 in Saccharomyces cerevi-
siae [15]. It was discovered as a 40-kDa and 357-amino
acid protein whose mRNA is ubiquitously expressed in
all tested human and mouse tissues, and most abun-
dantly in testis and ovaries [15]. Although at the time
its relevant Cdk was not known, its association with
RNAPII and potent in vitro and in vivo kinase activity
on the CTD of RNAPII was well documented [15]. This
activity was later associated with Cdk9, which was iden-
tified as a CycK interacting partner in a yeast two-
hybrid assay [16]. Since then, CycK has long been con-
sidered to be an alternative cyclin subunit of Cdk9,
together with CyclinT1 (CycT1) and two forms of
CyclinT2, CycT2a and CycT2b [17,18]. At that time, it
was also well-established that Cdk9 [in complex with
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tion factor b (P-TEFb)], is a crucial regulator of tran-
scriptional elongation via phosphorylation of Ser2 in the
CTD of RNAPII [19,20]. The lack of interest in further
characterizing the CycK/Cdk9 complex probably
stemmed from the discovery that CycT1/Cdk9 is the
only Cdk9 complex able to bind HIV Tat protein and
support HIV transcription [21]. This finding led the
large majority of Cdk9 research to focus on the CycT1/
Cdk9 complex, while CycK (and also CycT2) was only
marginally studied. The only major functional difference
between CycK and the CycT1/T2 subunits was noted by
the Peterlin lab: when these cyclins are artificially teth-
ered to a promoter, CycK activated transcription only
via RNA recruitment, while CycT1 and CycT2 by both,
RNA and DNA recruitment [22]. The first hints that
CycK might not be associated with Cdk9 came from
several mass spectrometry studies that failed to identify
CycK associated with human Cdk9 complexes [23,24].
This was followed by the discovery that Drosophila
Cdk12 interacts with CycK and the notion that
metazoan CycK protein sequences are most similar to
Ctk2, a cyclin partner of Ctk1 kinase, a yeast ortholog of
Cdk12 [6]. Finally, a recent study revealed that human
CycK is a 70-kDa and 580-amino acid protein with a C-
terminal proline-rich region [5]. It associates with
Cdk12 and Cdk13 in two separate complexes, but not
with its previously identified partner, Cdk9 [5].
Cdk12 and Cdk13
Cdk12 and Cdk13 were identified in cDNA screens for
cell cycle regulators. Because their cyclin partners were
not yet known, they were initially named CRKRS [25]
and CDC2L5 [26], respectively. They were found to be
1490- and 1512-amino acid proteins, respectively, with a
conserved central CTD kinase domain and degenerate
RS domains identified in their N- and C-terminal
regions [25-27]. Cdk12 was shown to phosphorylate
CTD of RNAPII, in vitro [25]. Based on the interaction
of Cdk12 and Cdk13 with overexpressed Cyclin L
(CycL), CycL was reported to be their regulatory subu-
nit, and the same studies suggested a role in the regula-
tion of alternative splicing [28,29]. However, recent
studies have reported that the endogenous Drosophila
Cdk12 and human Cdk12 and Cdk13 do not associate
with CycL, but rather with CycK [5,6]. In humans (and
likely in other higher organisms), CycK binds Cdk12
and Cdk13 in two separate complexes [5], while in Dro-
sophila, the related paralog of Cdk13 is missing and
there is only a CycK/Cdk12 complex [6,30,31].
Drosophila and human Cdk12 phosphorylate Ser2 in
the CTD of RNAPII, in vitro and in vivo [5,6], and
Cdk13 phosphorylates the CTD of RNAPII, in vitro [6].
The functional link between CycK and Cdk12 is strongly
supported by the overlapping set of genes affected by
the absence of CycK or Cdk12, and their common phe-
notypes leading to genomic instability [5,7]. The exact
function of the CycK/Cdk13 is not known.
A study by Bartkowiak et al. also showed that yeast
Ctk2/Ctk1 are homologs of CycK/Cdk12 (and Cdk13 in
mammals) and that yeast Bur2/Bur1 are homologs of
CycT/Cdk9 [6]. Since it was assumed for many years
that Cdk9 is a major Ser2 kinase in metazoan cells [20]
and that its Ser2 kinase activity is split in yeast between
its two homologs, Ctk1 and Bur1 [14], these findings
represent an important milestone in our knowledge of
Ser2 kinases and their relevant cyclin subunits. Table 1
provides a summary of information on the transcription
cycle-related Cdks, their cyclin partners, yeast homologs,
and kinase activity on the CTD of RNAPII. Of note, we
could not identify the previously described 40-kDa form
of CycK [15] at the level of mRNA or protein and were
unable to confirm any association of the 40- or 70-kDa
forms of CycK with Cdk9 in several cell lines [5].
Although we cannot completely exclude the possibility
that CycK interacts with Cdk9 at certain developmental
stages or under certain physiological conditions, the
conclusions of several publications that consider CycK a
bona fide partner of Cdk9 should be evaluated
cautiously.
Domain composition of CycK, Cdk12, and Cdk13
CycK has two N-terminal cyclin boxes and a C-terminal
proline-rich region (Figure 1A). The N-terminal struc-
ture of CycK resembles the classical cyclin composition,
with two cyclin boxes consisting of fifteen helices that
mediate binding to a Cdk partner [42]. The newly
described proline-rich region [5] consists of several pro-
line-rich motifs (PRMs; Figure 1A). Proteins with PRMs
are recognized for their function in transcriptional regu-
lation, RNA processing, and alternative splicing [43].
The domain composition of Cdk12 is comparable to
Cdk13 (Figure 1B). In both proteins, CTD kinase
domain is localized in the center (Figure 1B), consists of
about 300 amino acids, and their sequences are highly
similar (> 93%). They contain a PITAIRE motif at the
conserved position of the PSTAIRE motif found in yeast
cdc2 and related kinases [25,26]. Like the cdc2 ATP-
binding region, Cdk12 and Cdk13 also have characteris-
tic threonine and tyrosine residues at the beginning of
the ATP-binding region, implicating these residues in
the regulation of the kinase activity. Both kinases also
have a threonine in the activation ‘T-loop’ that is typi-
cally phosphorylated by a Cdk-activating kinase [25] and
reviewed in [44,45].
There are 20 and 17 arginine/serine rich (RS) motifs
in the N-terminus of Cdk12 and Cdk13, respectively
(Figure 1B). RS domains serve as docking sites for the
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cing factors and regulators of splicing [46,47]. Cdk12,
Cdk13, and CycK are localized in nuclear speckles,
subnuclear structures enriched in mRNA splicing fac-
tors [5,25,28]. The common presence of the RS and
CTD kinase domains in these Cdks makes them ideal
candidates for coupling CTD phosphorylation with
transcription and splicing [48-50]. Modulation of the
level of Cdk12 and Cdk13 protein in cells affects the
alternative splicing of certain splicing reporter con-
structs [27-29], and Cdk13 is suggested to be involved
in the phosphorylation of ASF/SF2 and in the alterna-
tive splicing of HIV [51]. However, these studies
involved the overexpression of Cdk12 and Cdk13,
without their relevant cyclin partner, and thus, their
direct roles in alternative splicing is still a matter of
future research. Notably, using splicing-sensitive
microarrays, we did not observe any significant splicing
defects in several genes that are differentially expressed
upon CycK or Cdk12 depletion [5].
Similar to CycK, PRMs are also present in the C-term-
inal region of both Cdks. In addition, Cdk12 carries one
more PRM motif in its central region and Cdk13 has
one in its N-terminus (Figure 1B). These PRMs may
serve as binding sites for SH3, WW, or profilin domain
containing proteins (reviewed in [52]). In contrast to
Cdk12, the N-terminus of Cdk13 contains an alanine-
rich motif with an unknown function. In addition, sev-
eral putative or verified bipartite and non-bipartite
nuclear localization signals have been described for both
kinases [25,28].
The CycK/Cdk12 complex phosphorylates Ser2 in
the CTD of RNAPII
RNAPII directs the transcription of protein coding
genes. The transcription process consists of several
stages, including preinitiation complex formation, pro-
moter clearance, pausing, productive elongation, and
termination [53,54]. This transcription cycle is tightly
linked to the co-transcriptional maturation of nascent
transcripts, including pre-mRNA splicing and polyade-
nylation [13,55]. RNAPII contains an unstructured
CTD with repeats of the evolutionarily conserved hep-
tapeptide, Y1S2P3T4S5P6S7, where individual serines
(Ser2, 5, and 7), threonine, and tyrosine can be phos-
phorylated [20,56-59]. Several Cdks and phosphatases
regulate the phosphorylation status of the CTD and
subsequent binding of transcription and pre-mRNA
processing factors [4]. Patterns of phosphorylation (and
other posttranslational modifications) of the CTD form
the so-called “CTD code”, which defines the action of
RNAPII during the transcription cycle and directs the
posttranscriptional processing of nascent transcripts
[8]. Our knowledge of phosphorylation events on the
CTD is based mostly on data obtained with phospho-
specific antibodies. However, the reactivities of the
antibodies are often affected by modifications on
neighboring residues and the concentration used. In
Table 1 Transcription-cycle related Cdks and their cyclin partners, yeast homologs, and kinase substrates
Cdk Other nomenclature Yeast homolog Cyclin Kinase activity on the CTD of RNAPII
Cdk7 CAK Kin28 CycH [32] Ser5 [33,34]
CAK1 Ser7 [34,35]
STK1
MO15
Cdk8 Srb10 CycC [36] CTD [37]
Cdk9-42 kDa PITALRE Bur1 [6] CycT1 [17,18] CycT2a/b [17,18] Ser2 [20]
Cdk9-55 kDa CycT1 [38]
Cdk11-46 kDa CycL1 [39]
CycL2 [39]
Cdk11-58 kDa CycL1 [39]
CycL2 [39]
CycD3 [40]
Cdk11-110 kDa PITSLRE Ste20 CycL1 [39,41] CTD [41]
CDC2L2 CycL2 [39,41]
Cdk12 CRKRS CRKS Ctk1 [6] CycK [5,6] Ser2 [5,6]
CRK7
PITAIRE
Cdk13 CDC2L5 Ctk1 [6] CycK [5] CTD [6]
PITAIRE
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individual repeats [57,60,61] (Saccharomyces cerevisiae
has 26, Drosophila has 44, and humans have 52 hepta-
peptide repeats [62]). Although these caveats should be
taken into account (discussed below), some aspects of
the CTD code and its role in the transcription cycle
are relatively well established. Unphosphorylated RNA-
PII is recruited to the promoter for preinitiation com-
plex assembly. Phosphorylation of Ser5 is a hallmark of
paused RNAPII and is mediated by Cdk7 during initia-
tion and promoter clearance. To release the paused
RNAPII and allow productive elongation, Ser2 is phos-
phorylated by Cdk9. In early elongation, Ser5 residues
are dephosphorylated, and the phosphorylation of Ser2
steadily accumulates to saturation while elongating on
the transcription unit. Termination results in depho-
sphorylation of the CTD, which makes the RNAPII
ready for another round of re-initiation (reviewed in
[4,20,56,63]). How do the CycK/Cdk12 and CycK/
Cdk13 affect phosphorylation of the CTD and regulate
gene expression? For a long time, Cdk9 was considered
to be the major elongation-associated Ser2 kinase in
mammalian cells [20]. However, recent studies have
found that Cdk12 phosphorylates Ser2, in vitro,a n d
depletion of Cdk12 results in at least a fifty percent
decrease in Ser2 levels in human cells [5,6].
 
 
Figure 1 Domain composition of CycK, Cdk12, and Cdk13. A) A schematic representation of the CycK domain structure. Two cyclin boxes
are depicted with a yellow and green ellipse, and the proline-rich domain by a violet oval. B) Schematic diagrams of Cdk12 and Cdk13 domain
structures. Putative or verified nuclear localization signals (NLS) are depicted by asterisks. Arginine/serine-rich (RS), proline-rich (PRM), alanine-rich
(A), and serine-rich (SR) domains are indicated by orange, green, violet, and purple ovals, respectively. A yellow asterisk represents the kinase
domain (KD). Numbers below the schemes indicate the amino acid position for a given domain.
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Ser2 phosphorylation has also been documented in
Drosophila, where Cdk12 also localized on several
active genes, in vivo, predominantly in the middle and
at the end of the transcriptional units [6]. In contrast,
knockdown of Cdk13 did not produce any observable
change in the levels of phosphorylated Ser2 [5,6]; how-
ever, subtle changes in the CTD phosphorylation were
observed [6]. Although Ser2 phosphorylation is thought
to be an important marker for the elongation of tran-
scripts of most protein-coding genes [64-66], depletion
of CycK and Cdk12 results in the downregulation of
only a small subset of genes (predominantly long and
complex ones) and in no change in the rate of global
transcription [5]. However, the downregulated genes,
including breast cancer type 1 (BRCA1), Fanconi ane-
mia complementation group I (FANCI),a n dataxia tel-
angiectasia and rad3-related (ATR) had less RNAPII
on their promoters and reduced amounts of nascent
transcripts, which is indicative of a transcriptional
defect [5]. Whether the diminished expression of a
subset of genes is due to aberrant co-transcriptional
processing, as suggested by the length and complexity
of CycK/Cdk12-dependent genes, is not currently
known. Notably, no global polyadenylation defects or
splicing defects in most of the down-regulated genes
were detected in the absence of CycK/Cdk12 [5].
A recent finding that Cdk12/13 and Cdk9 are homo-
logs of yeast Ctk1 and Bur1, respectively, provided
further insight into the possible role of Cdk12/13 and
Cdk9 kinases in metazoans [6]. In yeast, Ctk1 is respon-
sible for most of the Ser2 phosphorylation in promoter-
distal regions and most of the Ser2 phosphorylation in
bulk [67-69], while Bur1 contributes to the phospho-
Ser2 marks at the 5’ end of genes and the residual Ser2
phosphorylation [68,69]. Conspicuously, yeast deficient
in Ctk1 or phosphorylated Ser2 do not have transcrip-
tional defects [67,70,71], a finding consistent with results
in mammalian cells depleted of CycK and Cdk12 [5].
These findings are surprising considering the well-recog-
nized role of phosphorylated Ser2 in the regulation of
transcriptional elongation [64-66]. However, there are
alternative explanations. For example, upon depletion of
Ctk1 or Cdk12, phospho-Ser2-specific antibody does not
recognize phosphorylated Ser2 due to modification(s) of
neighboring residues in the CTD repeats. In a different
scenario, the absence of Ctk1 or Cdk12 results in differ-
ent patterns of CTD phosphorylation, compatible with
productive elongation. Alternatively, the functional out-
come of phosphorylated Ser2 depends on which indivi-
dual CTD repeat it is positioned on and by what kinase;
phospho-Ser2 marks at certain CTD repeats deposited
by the P-TEFb would direct transcription, while the
ones at different CTD repeats deposited by the CycK/
Cdk12 would be irrelevant for the efficiency of tran-
scription of most genes.
It was also shown that Ser2 is phosphorylated during
elongation by Ctk1, but Ctk1 is not required for associa-
tion of elongation factors with transcribing RNAPII [70].
A study by Kim et al. shows that depletion of Ctk1 leads
to the accumulation of RNAPII at the poly(A) sites of
genes with good consensus poly(A) sites [71], while the
distribution of RNAPII on other genes is unaffected
[70,71]. This finding corresponds to the suggested role
of Ser2 phosphorylation in 3’ end RNA processing [70].
More insight into the function of phosphorylated Ser2,
Cdk12, and Cdk9 was provided through the use of two
phospho-Ser2-specific antibodies, H5 and 3E10.
Whereas H5 predominantly recognizes phosphorylated
Ser2 in the context of the phosphorylated neighboring
Ser5 mark, 3E10 is more specific to CTD phosphory-
lated solely at Ser2 [60]. Loss of CycK/Cdk12 dimin-
ished the bulk levels of phosphorylated Ser2 to a similar
extent when measured by both antibodies. The result
was distinct from what was seen with depletion of Cdk9,
where a smaller decline in Ser2 phosphorylation was
observed when measured by the H5 antibody compared
to the 3E10 antibody [5]. Interestingly, experiments in
yeast suggest that there are two forms of Ser2 marks,
one recognized by H5, which is dephosphorylated prior
to termination, and another recognized by 3E10, which
is dephosphorylated just after termination [72].
Because Ser2 phosphorylation is a marker of elongat-
ing RNAPII and is thought to be crucial for coupling
transcription with mRNA-processing and other cellular
processes, future studies untangling the physiological
role of Cdk12 in these mechanisms promises to bring
exciting findings.
CycK/Cdk12 in the maintenance of genome
stability
Genome stability is crucial for the viability of the cell
and prevention of diseases, such as cancer, and is
mediated by the DDR pathways [73,74]. Genome stabi-
lity is maintained through the cooperation of hundreds
of DDR proteins that detect lesions and mediate their
repair [75,76]. Reparation of each type of DNA lesion
requires the action of a specific group of DDR proteins.
BRCA1, ATR, ataxia telangiectasia mutated (ATM), and
Fanconi anemia proteins are at the core of several DDR
pathways and are crucial for the maintenance of genome
stability [77-79]. Many new players and cellular pro-
cesses essential for the maintenance of genome stability
have been identified from recent genome-wide screens
[80]. Pathways and factors with little explored connec-
tion to DDR, including those involved in transcription
and mRNA processing, were identified in several screens
[75,76,81]. Notably, transcriptional cyclin-dependent
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were functionally linked to the DDR and the mainte-
nance of genome stability via regulation of transcription
and mRNA processing [82,83].
Our work showed that the expression of several DDR
genes, including some core players involved in the main-
tenance of genome stability, is CycK/Cdk12-dependent
[5,7]. At least in the case of BRCA1, ATR, and FANCI,
the regulation is at the transcriptional level [5,7]. In
accordance with the observed down-regulation of many
DDR genes, cells without CycK/Cdk12 induce sponta-
neous DNA damage signaling, as indicated by the accu-
mulation of 53BP1 and g-H2AX foci and an increased
number of cells in the G2-M phase [5]. Cells depleted
of CycK/Cdk12 are sensitive to various DNA damaging
agents, including camptothecin, mitomycin C, and eto-
poside. These compounds cause various types of DNA
lesions, and this sensitivity of CycK/Cdk12-depleted
cells to various types of DNA damage is consistent with
the proposed broad role of this complex in the DDR
and maintenance of genome stability [5,7]. CycK was
also independently identified in a genome-wide screen
for proteins mediating resistance to the DNA damage-
inducing compound, camptothecin [81].
A recent study by Yu et al. suggests a direct role for
CycK in replication stress response [84]. Cells depleted
of CycK show impaired cell cycle recovery after chal-
lenge with hydroxyurea and amphidicolin [84]. However,
this result can also be explained by the indirect effect of
decreased expression of ATR, the replication stress
response regulator, in CycK-depleted cells [5]. The con-
clusion of this study is also complicated by the fact that
CycK was studied as a cyclin subunit of Cdk9 [84].
Although a weak interaction of CycK with ATR was
detected [84], the possibility of a direct role for CycK/
Cdk12 in the replication stress response requires more
research. Another line of evidence supporting a role for
CycK in the DDR comes from the p53-dependent
expression of CycK in response to treatment with adria-
mycin, ultraviolet, or gamma irradiation [85].
Supported by biochemical, functional, and the evolu-
tionary characterization of the CycK/Cdk12 and CycT/
Cdk9 complexes [5,6], it is conceivable that both contri-
bute to the maintenance of genome stability, but through
different mechanisms. The CycK/Cdk12 complex main-
tains genome stability through the regulation of DDR
gene expression [5,7]. Consistently, its yeast homolog,
Ctk2/Ctk1, is also implicated in the expression of several
DDR genes, and a mutation in the Ctk1 kinase domain
renders cells sensitive to DNA damage [83]. In contrast,
the function of Cdk9 and its yeast homolog, Bur1, in the
maintenance of genome integrity appears to be direct
and independent of the modulation of DDR gene expres-
sion, as judged by results from genome-wide expression
arrays [84,86]. Cdk9 was found in complex with replica-
tion stress response proteins ATR, ataxia telangiectasia
and Rad3-related interacting protein (ATRIP), and clas-
pin, and, upon replication stress, it localizes to chromatin
to eliminate the collapse of stalled replication forks [84].
The kinase activity of Cdk9 seems to be essential for cell
cycle recovery after replication stress, but whether the
CTD of RNAPII or other Cdk9-associated proteins are
substrates mediating this function is unknown [84]. Nota-
bly, the 55-kDa, but not the 42-kDa isoform, of Cdk9 was
shown to associate with Ku70, a protein directly involved
in DNA repair by non-homologous end-joining [87]. In
yeast, Bur1 binds the Rfa1 protein that protects ssDNA
and maintains genome stability during DNA replications
stress [86]. Deletion of the Rfa1-binding domain in Bur1
renders cells sensitive to hydroxyurea and methanesulfo-
nate [86].
Cdk12 and Cdk13 in disease
Considering that Cdk12 regulates the expression of sev-
eral cancer-related genes, such as BRCA1 [5,7], it comes
as no surprise that the dysregulation of Cdk12 has been
identified in several cancers. A comprehensive genomic
approach identified Cdk12 to be one of the most fre-
quently somatically mutated genes in high-grade serous
ovarian cancer, the most fatal form of the disease [88].
Next to the nonsense and indel mutations that lead to
the loss of protein function, several point mutations in
the kinase domain have also been identified [88]. This
finding points to the critical importance of the kinase
activity of Cdk12 for the development/progression of
this disease. Since about half of the ovarian cancer sam-
ples were defective in homologous recombination (HR)
[88], we can speculate that the aberrant CTD kinase
activity of Cdk12 results in the down-regulation of sev-
eral HR regulators [5,7], and defective HR can lead to
the development of the disease [7].
Several pieces of evidence also point to an important
role for Cdk12 in the development of breast cancer.
Notably, Cdk12 is located on chromosome 17, within
the 17q21 locus that contains several candidate genes
for breast cancer susceptibility [89,90], and it is co-
amplified with the tyrosine kinase receptor ERBB2, a
protein amplified and overexpressed in about 20% of
breast tumors [91,92]. Gene fusion between Cdk12 and
ERBB2 was also detected in gastric cancer [93]. Cdk12
is also implicated in the modification of tamoxifen sensi-
tivity in estrogen-positive breast cancer via the modula-
tion of the mitogen-activated protein kinase pathway
[94]. Interestingly, decreased expression of BRCA1 was
linked to the occurrence of sporadic breast cancer and
is correlated with a poor prognosis for patients [95,96];
however, the mechanism of this aberrant expression is
poorly understood.
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cance of Cdk13. Increased levels of Cdk13 were found
in patients with refractory anemia with ringed sidero-
blasts, associated with marked thrombocytosis, a disease
caused by ineffective hematopoiesis [97]. Another report
demonstrates that Cdk13 is necessary for megakaryocyte
d e v e l o p m e n t[ 9 8 ] .I th a sb e en suggested that Cdk13
affects the splicing of HIV and might act as its restric-
tion factor [51] and that CycK inhibits HIV expression
by interfering with CycT1/Cdk9 complex formation in a
Nef-dependent manner [99].
Evidence is accumulating that the aberrant phosphoryla-
tion of CTD correlates with the onset and progression of
many diseases (for example, cardiac hypertrophy [100],
leukemia [101-103], and HIV [20,104,105]. Thus, the iden-
tification of Cdk12, along with Cdk9, as the major Ser2
kinases, makes these attractive candidate targets for the
development of small chemical inhibitors as therapeutic
agents. At present, approximately 30 compounds are
known to inhibit Ser2 phosphorylation in the CTD [106].
Among them, DRB and flavopiridol are mostly used in
research studies to inhibit Cdk9. It will be of great interest
to validate the ability of these compounds to inhibit the
Ser2 kinase activity of Cdk12 and to compare their effects
with the inhibition of Cdk9. So far, it has been suggested
that flavopiridol, the most specific inhibitor of Cdk9
[64,107], does not inhibit Cdk12 and Cdk13 in concentra-
tions sufficient for the inhibition of Cdk9 [63].
CycK in development
CycK complexes play a crucial role in embryo develop-
ment, as genetic inactivation of CycK in mice leads to a
lethal phenotype at the stage of the morula-blastocyst
transition [5]. However, currently we can only speculate
about the specific function of the CycK complexes in
embryo development. It is possible that CycK com-
plexes, through regulating phosphorylation of the CTD
of RNAPII, direct the expression of genes important for
the transition of individual developmental stages.
Although, no aberrant expression of genes known to be
involved directly in development was detected when
CycK or Cdk12 were depleted in human cell lines [5],
more physiologically relevant experiments in CycK
knock-out mouse embryonic stem cells could better
address this question. Genetic inactivation of other
cyclin/Cdk complexes involved in CTD phosphorylation
results in an embryonic lethal phenotype. For example,
inactivation of CycT2 leads to the death of embryos at
4-cell stage and depletion of CycT2 in mouse embryonic
stem cells affects the expression of Lefty1 and Lefty2,
important regulators of early development [108]. Cdk8
was shown to be essential for preimplantation mouse
development, perhaps by affecting the transcriptional
repression of genes critical for an early cell fate
determination [109]. Dysregulated expression of genes
responsible for DDR and the regulation of basic pro-
cesses in the cell could be another reason for the
embryonic lethal phenotype of the CycK knock out
mice [5]. In support of this hypothesis, knock out of
some members of the DDR pathways, such as ATR
[110,111] and BRCA1 [112], also lead to early embryonic
lethality in mice. The monitoring of CycK expression in
embryos by the activity of the beta-galactosidase gene
under the control of an endogenous CycK promoter
revealed that CycK is globally expressed in embryos at
different embryonic stages [5]. This observation corre-
lates with the proposed function of CycK in early
embryo development. Interestingly, the most distinct
signal was observed in the formation of neural tube and
brain structures at embryonic day 8.5 [5], suggesting an
important role for CycK in the process of neurogenesis.
In agreement with this observation, CycK was identified
as one of the factors necessary for the development of
nervous system in Drosophila [113]. A study performed
in Xenopus laevis showed that recruitment of CycK and
CycT2 has different effects on the endoderm-inducing
activity of the homeodomain protein, Mix.3 [114].
Perspective
Although research of CycK, Cdk12, and Cdk13 is at an
early stage, recent studies have already uncovered several
pieces of evidence of these proteins’ significant medical
relevance. In the next few years, we should learn more
about these proteins’ roles in regulation of transcription,
posttranscriptional mRNA processing, and other CTD
RNAPII-regulated cellular functions. These studies should
reveal more about the function of these proteins in cellular
processes, human disease, and embryonic development.
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